M
Mytos
Infrastructure for fully automated manufacture of any human cell type
About Mytos
Mytos.bio is a pioneering company in the biotech sector, specializing in the fully automated manufacture of human cell types. The company serves large biotechnology firms, particularly those involved in cell therapies and traditional drug development. Operating in the high-growth biotech market, Mytos.bio leverages advanced robotics and software to transform cell culture from an artisan process to a scalable, automated one. This innovation allows their clients to scale cell production without increasing headcount, ensuring consistent high-quality cells every time. Mytos.bio's business model revolves around selling and pre-ordering their proprietary Mytos Platform to top-tier biotech companies, generating revenue through these sales and ongoing support services. The company is backed by a team of top-tier hardware engineers, software engineers, and biologists, and has garnered significant attention, including being a YCombinator alumnus and featuring in Forbes 30 Under 30.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- London, United Kingdom
- Employees
- 48
- Open positions
- 1
- Dealroom signal
- 77.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Tech for Biotech and Pharma, Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing, SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $19M | $76M | Buckley Ventures · Wing Venture Capital · IQ Capital | ↗ |
| OtherOther financing | Jul 2022 | $0 | — | TBD Angels | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mytos is 9.4K monthly website visits, up 91.8% over the last three months. Mytos's team declined 2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Y Combinator
Acequia Capital
Deep Science Ventures
Tiny Supercomputer Investment Company
Cathexis ventures
Series A3 investors entered at this stage
Buckley Ventures
Wing Venture Capital
IQ Capital
Other known investors8 additional known investors
TBD Angels
Ahmed Medhat
Charlie Songhurst
Cur8 Capital
Emles Venture Partners
Jude Gomila
TGM
The Automation Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mytos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mytos’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.